QUACK: Examination of relationship between quality of life and adverse events in the first -line treatment including cetuximab for KRAS wild-type unresectable colorectal cancer (clinicaltrials.gov) - Sep 25, 2026 - P=N/A | N=140 | Active, not recruiting | Sponsor: Epidemiological and Clinical research Information Network (ECRIN) | Unknown status ➔ Active, not recruiting
Adverse events • Enrollment closed • HEOR • Colorectal Cancer • Oncology • Solid Tumor • EGFR • KRAS
|